Phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors

Category Primary study
JournalCancer Research
Year 2019
This article has no abstract
Epistemonikos ID: f87b12183f94ff40d027a398a6bb277a85d651b7
First added on: Feb 11, 2025